These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36941812)

  • 1. Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India.
    Mohan JC; Sathyamurthy I; Panja M; Agarwala R; Ponde CK; Kumar AS; Mahala BK; Kolapkar V; Kumar RVL; Patel K
    Curr Cardiol Rev; 2023; 19(5):97-106. PubMed ID: 36941812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.
    Hartmann C; Bosch NL; de Aragão Miguita L; Tierie E; Zytinski L; Baena CP
    Int J Clin Pharm; 2018 Dec; 40(6):1443-1453. PubMed ID: 30173307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?].
    Kanorskiy SG; Borisenko YV
    Kardiologiia; 2018 Jun; 58(6):85-89. PubMed ID: 30362441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction.
    Pay L; Yumurtaş AÇ; Tezen O; Çetin T; Keskin K; Eren S; Çinier G; Hayıroğlu Mİ; Çınar T; Tekkeşin Aİ
    Rev Assoc Med Bras (1992); 2023; 69(12):e20230703. PubMed ID: 37971125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction.
    Tóth N; Soós A; Váradi A; Hegyi P; Tinusz B; Vágvölgyi A; Orosz A; Solymár M; Polyák A; Varró A; Farkas AS; Nagy N
    Can J Physiol Pharmacol; 2021 Nov; 99(11):1159-1174. PubMed ID: 34636643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of ivabradine in cardiogenic shock.
    Chiu MH; Howlett JG; Sharma NC
    ESC Heart Fail; 2019 Oct; 6(5):1088-1091. PubMed ID: 31332966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure.
    Hori M; Imamura T; Nakamura M; Kinugawa K
    Intern Med; 2021 Mar; 60(6):897-900. PubMed ID: 33087678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
    Chow SL; Page RL; Depre C
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
    Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC
    ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
    Roth S; Fernando C; Azeem S; Moe GW
    Adv Ther; 2017 Jun; 34(6):1340-1348. PubMed ID: 28432646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
    Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M
    Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
    Mentz RJ; DeVore AD; Tasissa G; Heitner JF; Piña IL; Lala A; Cole RT; Lanfear DD; Patel CB; Ginwalla M; Old W; Salacata AS; Bigelow R; Fonarow GC; Hernandez AF
    Am Heart J; 2020 May; 223():98-105. PubMed ID: 32217365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of Ivabradine in the Contemporary Era.
    Imamura T
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: The largest report from India.
    Chopra VK; Mittal S; Bansal M; Singh B; Trehan N
    Indian Heart J; 2019; 71(3):242-248. PubMed ID: 31543197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine for the treatment of chronic heart failure.
    Henri C; O'Meara E; De Denus S; Elzir L; Tardif JC
    Expert Rev Cardiovasc Ther; 2016; 14(5):553-61. PubMed ID: 26967048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
    Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA
    Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.